Background: Weight change post-kidney transplantation and its associations in Aboriginal and Torres Strait Islander Australians, a group known to have poor patient and graft outcomes, are unknown. Weight change based on body mass index in Aboriginal and Torres Strait Islander Australian recipients was compared to non-indigenous recipients.

Methods: We performed a cohort analysis of data from the Australia and New Zealand Dialysis and Transplant Registry for first deceased donor kidney transplant recipients between 1995 and 2014 in Australia. Weight change post-kidney transplantation was analysed by recipient ethnicity using multivariate mixed effect linear regression analysis.

Results: There were 343 (5.24%) Aboriginal and Torres Strait Islander Australian kidney transplant recipients from a total of 6550 recipients. They had higher pre-transplant BMI ($p < 0.001$), higher rates of current smokers ($p < 0.001$), diabetes ($p < 0.001$), coronary artery disease ($p < 0.001$), cerebrovascular disease ($p = 0.011$) and peripheral vascular disease ($p = 0.013$), ≥4 HLA mismatches ($p < 0.001$), graft loss ($p < 0.001$), mortality ($p < 0.001$) and rejection rates ($p < 0.001$). Weight increased in the first 2 years post-transplantation in both Aboriginal and Torres Strait Islander Australians and non-indigenous Australians. After adjusting for the baseline differences, weight change diverged significantly at 6, 12 and 24 months. The difference was most marked between 6 and 12 months. When stratified by pre-transplantation BMI, all groups except underweight reflected this pattern. Normal weight and obese Aboriginal and Torres Strait Islander Australian recipients had substantial increase at 12 and 24 months and overweight at 6, 12 and 24 months. The difference in BMI trajectories between Aboriginal and Torres Strait Islander Australians and non-indigenous Australians persisted after adjustment in multivariate mixed effect linear regression analysis.

Conclusions: Post-kidney transplantation weight gain in this high-risk population is substantial and greater than in non-indigenous Australians. Further studies should assess the effect of treatment factors and weight gain on transplant and recipient outcomes.

Keywords: End stage kidney disease, Transplantation, Body mass index, Weight change trajectory, Aboriginal and Torres Strait islander Australians, Outcomes
Background
Weight gain in non-indigenous kidney transplant recipients is common and predicts outcomes for patient and graft survival [1–3]. Weight changes and their associations in Aboriginal and Torres Strait Islander Australians after kidney transplantation are unknown. In the non-indigenous population, post-transplantation weight gain has been reported at between 10 and 35%, with the majority of the weight gain occurring in the first 12 months post-transplantation [4–7].

Significant weight gain post-kidney transplantation in non-indigenous patients is associated with a number of negative outcomes including post-transplant hypertension [8], chronic allograft nephropathy [2, 9], new onset diabetes after transplantation [9], and death with a functioning graft [1, 5, 10–12]. There is a paucity of similar data in Aboriginal and Torres Strait Islander transplant recipients; a group with known inferior transplant outcomes [13], lower transplantation rates [14] and high burden of end stage kidney disease requiring renal replacement therapy [15].

In general, Aboriginal and Torres Strait Islander Australian adults are 2.6 times as likely as non-indigenous adults to smoke daily, 1.2 to 1.6 times as likely to be overweight or obese, and 1.2 times as likely to have high blood pressure [16, 17]. They have higher rates of cardiovascular disease, are 3.5 times as likely to have diabetes and 2 to 4 times as likely to have biomedical signs of chronic kidney disease requiring renal replacement therapy [15].

There are many postulated associations with the tendency to increased weight and obesity in Aboriginal and Torres Strait Islander Australians which include various geographical, social, economic and infrastructure factors that affect food choices and availability [17, 18].

Overweight and obesity are casually linked with cardiovascular disease, including coronary heart disease, stroke, heart failure and their associated risk factors [19]. It is presently unknown if Aboriginal and Torres Strait Islander Australians gain weight post-transplantation. If this occurs, the amount, timing, distribution and metabolic effects and impact on patient and graft survival are unclear.

We aimed to examine the weight change trajectories of body mass index (BMI) in Aboriginal and Torres Strait Islander kidney transplant recipients and compare with their non-indigenous counterparts.

Methods
Study design
We performed a cohort analysis using the Australia and New Zealand Dialysis and Transplant Registry which collects data on all kidney transplant recipients from hospitals across Australia and New Zealand.

Participants and data extraction
ANZDATA collects observational data on all patients receiving chronic renal replacement therapy in Australia. All data are collected and submitted to ANZDATA by the treating nephrologist or renal health team at each local site. Data was extracted on all deceased donor recipients in Australia aged ≥18 years, Aboriginal and Torres Strait Islander and non-indigenous, who received a single organ first kidney transplant over the 20 years from 1995 to 2014.

Data extracted included age at transplantation, gender, ethnicity (Aboriginal and Torres Strait Islanders and non-indigenous), transplant era (1995–1999, 2000–2004, 2005–2009, 2010–2014), the number of human leukocyte antigen (HLA) mismatches, dialysis modality and vintage, and recipient comorbidities including hypertension, cardiovascular and peripheral vascular disease, diabetes mellitus, smoking status, BMI (see below), and donor-related factors (donor age and gender) and the duration of total ischemia, delayed graft function, prednisolone dose and rejection. The detailed definitions and measurement of each variable and characteristics can be found in the ANZDATA survey instruction material at http://www.anzdata.org.au/forms/2013SurveyInstructions_v2014.pdf.

Examining changes in body mass index
BMI was calculated from the quotient of the weight and the square of the height at the time of transplantation. We examined rates of changes in BMI from transplantation using weights at 3, 6, 12 and 24 months post-transplantation. Patterns were compared between Aboriginal and Torres Strait Islander and non-indigenous recipients. Further analyses stratified recipients based on BMI at time of transplantation: underweight (BMI < 18.5 kg/m²), normal weight (BMI 18.5–24.9), overweight (BMI 25–29.9), and obese (BMI ≥ 30) [20].

Statistical analysis
Descriptive statistics were expressed as mean and standard deviation for discrete and continuous measures. Percentages were reported for categorical variables. Independent sample T-test and Chi-square analyses were conducted to determine the differences of recipients’ baseline characteristics between Aboriginal and Torres Strait Islander and non-indigenous groups.

A multivariate mixed effect linear regression model was applied to fit linear mixed models of weight trajectories. As the outcome (weight) occurred for each participant at repeated time points, a mixed (random) effect models was used to account for the hierarchical structure of the data. The fixed effects were the group effect (Indigenous vs non-indigenous groups), time effect (Baseline, 3, 6, 12 and 24 months), and group x time interaction and were analogous to regression coefficients. The
random effect represented the estimated variability in the intercept (random intercept for patients) to account for repeated measurements. The model was adjusted by the baseline measure of outcome variable. Maximum likelihood estimate procedure was used to compare the significant differences of BMI over time and between Aboriginal and Torres Strait Islander and non-indigenous groups. Univariate models were first used to explore the association between Indigenous status and the change in BMI. A multivariate modelling approach was then undertaken by adding variables considered clinically important or statistically significant from the univariate model, to adjust for confounding. A series of models were undertaken by adding and subtracting variables, with changes in model fit assessed by log likelihood to choose the final multivariate model. The two-sided test was performed for all analysis and the level of significance was set at $p < 0.05$. All analyses were performed using STATA software version 14.1 (StataCorp 2014©1985–2014 StataCorp LP).

The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the 'Declaration of Istanbul on Organ Trafficking and Transplant Tourism'.

**Results**

**Baseline characteristics**

There were 6550 first time, single organ deceased donor kidney transplant recipients in Australia from 1995 to 2014. 343 (5.24%) recipients were Aboriginal and Torres Strait Islander Australians (Fig. 5). The differences between the two groups are shown in Table 1. Aboriginal and Torres Strait Islander Australians had higher baseline BMI at the time of transplantation, higher rates of current smokers, diabetes mellitus, coronary artery disease, cerebrovascular disease and peripheral vascular disease. Aboriginal and Torres Strait Islander recipients had longer median total ischaemia time, higher rates of ≥4 human leucocyte antigen (HLA) mismatches, longer dialysis vintage, higher rates of graft loss and higher mortality rate. Rates of rejection, delayed graft function and prednisolone dose were higher among the Aboriginal and Torres Strait Islander vs non-indigenous recipients.

There were no significant differences in the overall immunosuppression.

**Weight change trajectories: comparison between aboriginal and Torres Strait islander and non-indigenous recipients**

**Weight change after adjusting for baseline differences**

Median BMI increased significantly in the first 2 years after transplantation in both groups (Fig. 1). Using a mixed effect model to adjust for the baseline differences, both groups had similar weight change trajectories for the first 3 months but then diverged significantly, with a positive change of 0.34 kg/m$^2$ (0.09 kg/m$^2$–0.59 kg/m$^2$), 0.66 kg/m$^2$ (0.40 kg/m$^2$–0.92 kg/m$^2$) and 0.50 kg/m$^2$ (0.22 kg/m$^2$–0.78 kg/m$^2$) at 6, 12 and 24 months respectively in the Aboriginal and Torres Strait Islander group mean BMI compared with the non-indigenous group (Fig. 2). The difference in the rate of BMI change between the two groups was most marked between 6 and 12 months post-transplantation.

**Weight change by baseline BMI strata at the time of transplantation**

When stratified by BMI at the time of transplantation, all groups except underweight patients reflected this overall pattern of increasing BMI. Compared with the change in their non-indigenous counterparts, normal weight Aboriginal and Torres Strait Islanders recipients had significantly increased mean BMI gain at 12 and 24 months (Fig. 3a), overweight Aboriginal and Torres Strait Islander recipients had significantly elevated BMI at 6, 12 and 24 months (Fig. 3b), while obese Aboriginal and Torres Strait Islander recipients had increased mean BMI that reached statistical significance at 12 and 24 months (Fig. 3c). However, underweight Aboriginal and Torres Strait Islander recipients had similar BMI changes up to 6 months post-transplant, but at 24 months, had a significant lower BMI compared with the non-indigenous group (Fig. 3d).

**Weight change after adjusting for confounders and pre-existing risk factors at the time of transplantation**

As shown in Table 2, using multivariate mixed effect models accounting for confounders shown in Table 1, the difference in weight trajectories between Aboriginal and Torres Strait Islander and non-indigenous transplant recipients persisted with a significant difference favouring a higher BMI in the Aboriginal and Torres Strait Islander group at 6, 12 and 24 months. A significant association with BMI was also observed for younger recipient and donor, recipients with coronary artery disease and longer total ischaemia time.

**Weight change after adjusting for post-transplantation factors**

When the post-transplantation factors (rejection, delayed graft function and prednisolone dose) were added (model 2, Table 2), the same factors remained significant in addition to the significant association with delayed graft function and prednisolone dose. Surprisingly, for differences between Aboriginal and Torres Strait Islander and non-indigenous Australians the occurrence of rejection had no statistically significant association.
## Table 1 Recipient’s baseline characteristics based on Indigenous status

| Characteristic                                      | Non-Indigenous* | Indigenous* | \( P \) value** |
|-----------------------------------------------------|-----------------|-------------|-----------------|
| Age (years) at transplantation, Mean (SD)           | 50 (12.3)       | 45.7 (10.1) | < 0.001         |
| Male, n (%)                                         | 3904 (62.9)     | 185 (53.9)  | < 0.001         |
| Current Smoker, n (%)                               | 746 (12)        | 94 (27.4)   | < 0.001         |
| Diabetes mellitus, n (%)                            | 911 (14.7)      | 170 (49.6)  | < 0.001         |
| Coronary artery disease, n (%)                      | 1109 (17.9)     | 98 (28.6)   | < 0.001         |
| Cerebrovascular disease, n (%)                       | 326 (5.3)       | 29 (8.5)    | 0.011           |
| Peripheral vascular disease, n (%)                  | 596 (9.6)       | 47 (13.7)   | 0.013           |
| Total ischaemia time, Median (IQR)                  | 13.0 (10.0, 16.0)| 16.0 (12.0, 20.0)| < 0.001         |
| Mismatch n (%)                                       |                 |             | 0.001           |
| 0                                                   | 259 (4.2)       | 1 (0.3)     |                |
| 1                                                   | 685 (11.0)      | 20 (5.8)    |                |
| 2                                                   | 1466 (23.6)     | 34 (9.9)    |                |
| 3                                                   | 1078 (17.4)     | 33 (9.6)    |                |
| 4                                                   | 960 (15.5)      | 58 (16.9)   |                |
| 5                                                   | 1126 (18.1)     | 111 (32.4)  |                |
| 6                                                   | 633 (10.2)      | 86 (25.1)   |                |
| Transplant era, n (%)                               |                 |             | 0.71            |
| 1995–1999                                           | 1254 (20.2)     | 64 (18.7)   |                |
| 2000–2004                                           | 1309 (21.1)     | 73 (21.3)   |                |
| 2005–2009                                           | 1386 (22.3)     | 85 (24.8)   |                |
| 2010–2014                                           | 2258 (36.4)     | 121 (35.3)  |                |
| Dialysis vintage, n (%)                             | 230 (3.7)       | 5 (1.5)     | < 0.001         |
| Pre-emptive                                        |                 |             |                |
| < 1 year                                           | 573 (9.2)       | 18 (5.2)    |                |
| 1–5 years                                          | 805 (61.3)      | 206 (60.1)  |                |
| > 5 years                                          | 1599 (25.8)     | 114 (33.2)  |                |
| BMI at time of transplant (kg/m²), Mean (SD)        | 26.3 (4.7)      | 27.6 (5.7)  | < 0.001         |
| BMi at time of transplant (kg/m²), n (%)            |                 |             | < 0.001         |
| < 18.5                                             | 176 (2.8)       | 9 (2.6)     |                |
| 18.5–24.9                                          | 2415 (38.9)     | 103 (30.0)  |                |
| 25–29.9                                            | 2192 (35.3)     | 113 (32.9)  |                |
| > 30                                               | 1281 (20.6)     | 104 (30.3)  |                |
| Dialysis modality before transplantation             |                 |             | < 0.001         |
| HD                                                  | 4597 (74.1)     | 294 (85.7)  |                |
| PD                                                  | 1588 (25.6)     | 49 (14.3)   |                |
| Rejection, n (%)                                    | 1531 (24.7)     | 118 (34.4)  | < 0.001         |
| Delayed graft function, n (%)                       | 1554 (25.0)     | 123 (35.9)  | < 0.001         |
| Prednisolone doses (mg), n (%)                      |                 |             | < 0.01          |
| 0                                                   | 427 (6.9)       | 31 (9.0)    |                |
| 1–4.99                                             | 230 (3.7)       | 11 (3.2)    |                |
| 5–6.99                                             | 2039 (32.9)     | 81 (23.6)   |                |
| 7–9.99                                             | 1062 (17.1)     | 45 (13.1)   |                |
| 10+                                                | 1520 (24.5)     | 103 (30.0)  |                |
| Donor age (years)                                   | 44.2 (17.5)     | 44 (17.5)   | 0.77            |
| Donor male, n (%)                                   | 3575 (57.6)     | 201 (58.6)  | 0.72            |

*Some characteristics do not add up to 100% due to missing cases for that characteristic

**\( P \) values are based on Chi-square test for percentages, independent sample t-test for means and Mann Whitney U test for medians

HD Haemodialysis, PD Peritoneal Dialysis
with BMI. However, after stratifying by rejection and analysing the BMI trajectories between Aboriginal and Torres Strait Islander and non-indigenous group, the BMI was significantly higher for the occurrence of rejection in the Aboriginal and Torres Strait Islander patients (compared to non-indigenous) than for the patients who did not have any rejection (Table 4). These post-transplantation factors (delayed graft function and prednisolone dose) may partly explain the observed weight trajectories post-transplantation.

There was no overall trend in the BMI change post-transplantation across immunosuppression regimens, although there was a non-statistically significant tendency to higher BMI in those on tacrolimus and mycophenolate sodium (Table 3 and Fig. 4).

There was no statistically significant cohort effect (that is, being transplanted in the periods 1995–1999, 2000–2004, 2005–2009, 2010–2014) on weight gain in the first 24 months post-kidney transplantation between the two groups.

---

**Fig. 1** Box plot representing observed BMI at transplantation and 3, 6, 12 and 24 months post-transplantation in Aboriginal and Torres Strait Islander vs Non-Indigenous Australians. Data shown are median, inter-quartile range, minimum and maximum BMI.

**Fig. 2** Weight trajectories in Aboriginal and Torres Strait Islander vs Non-Indigenous transplant recipients over the first 2 years after transplant. The lines show the estimated marginal means from mixed effect linear model at 0, 3, 6, 12 and 24 months.
Discussion

This is the first study to assess weight change trajectories among Aboriginal and Torres Strait Islander Australian kidney transplant recipients, a group with high background rates of metabolic disease, poorer access to transplantation and post-transplantation outcomes. The main findings are: 1) there are substantial differences between Aboriginal and Torres Strait Islander and non-indigenous patients in the baseline clinical characteristics potentially associated with weight gain and cardiovascular risk post-kidney transplantation 2) Aboriginal and Torres Strait Islander Australian kidney transplant recipients had both higher prevalence of overweight and higher absolute BMI preceding transplantation than non-indigenous patients, 3) although there is an increase in weight gain in both groups in the first 2 years, this increase is substantially higher in Aboriginal and Torres Strait Islander Australians, 4) Predictors of weight gain included young age, female gender, longer total ischemia time, cardiovascular disease, older donor age, delayed graft function and prednisolone dose and 5) although there is an association between post-transplantation factors (delayed graft function and prednisolone dose) and BMI, the association with rejection was only apparent after stratifying BMI trajectories between Aboriginal and Torres Strait Islander and non-indigenous group by rejection (rejection or no rejection) (Table 4).

The increase in weight observed in the first 24 months in both groups is consistent with post-transplantation weight gain seen in non-indigenous patients in other populations [5]. The striking difference in the results of this study is the higher weight gain in Aboriginal and Torres Strait Islander Australians. This may be explained by the higher baseline BMI, which is consistent with findings in other studies comparing BMI between the two groups, [19] and other substantial differences between Aboriginal and Torres Strait Islander and non-indigenous Australians in other baseline risks of obesity at transplantation (Table 1) [15, 21].

Studies of post-transplantation outcomes in Aboriginal and Torres Strait Islander Australians suggest the poorer
| Variables                                | Univariate Model [1] |                  |                  |                  | Multivariate Model 1² |                  |                  |                  | Multivariate Model 2³ |                  |                  |                  |                  |
|-----------------------------------------|----------------------|------------------|------------------|------------------|-----------------------|------------------|------------------|------------------|-----------------------|------------------|------------------|------------------|------------------|
|                                        | Coefficient [4]      | RE % [5]         | P value          | Coefficient [4]  | (95% CI)              | RE % [5]         | P value          | Coefficient [4]  | (95% CI)              | RE % [5]         | P value          | Coefficient [4]  | (95% CI)        |
|                                        | (95% CI)             |                  |                  | (95% CI)         |                  |                  |                  | (95% CI)         |                  |                  |                  |                  |
| Indigenous status                      | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| Non-indigenous                         | –                    | –                | –                | 0.06 (–0.18–0.30) | 62                   | 0.0618            | 0.618            | –                | –                    | –                | –                |
| Indigenous                             | 0.06 (–0.18–0.30)    | 62               | 0.0618           | 0.005 (–0.29–0.19) | –9                    | 0.687            | –                | –0.04            | (–0.32–0.23)        | –4.1             | 0.765            |
| Time post-transplant (months)          | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| 0                                      | –                    | –                | –                | 0.29 (0.24–0.35)  | 34.2                  | <0.001           | 0.30 (0.24–0.35) | 34.7            | <0.001            | 0.33 (0.27–0.39) | 39.2             | <0.001            |
| 3                                      | 0.29 (0.24–0.35)     | 34.2             | <0.001           | 0.30 (0.24–0.35) | 34.7                  | <0.001           | 0.33 (0.27–0.39) | 39.2            | <0.001            | 0.33 (0.27–0.39) | 39.2             | <0.001            |
| 6                                      | 0.80 (0.75–0.86)     | 123.2            | <0.001           | 0.81 (0.75–0.86) | 123.9                 | <0.001           | 0.84 (0.78–0.90) | 132.6           | <0.001            | 0.84 (0.78–0.90) | 132.6            | <0.001            |
| 12                                     | 1.23 (1.18–1.29)     | 243.1            | <0.001           | 1.24 (1.18–1.29) | 243.1                 | <0.001           | 1.26 (1.20–1.32) | 251.4           | <0.001            | 1.26 (1.20–1.32) | 251.4            | <0.001            |
| 24                                     | 1.46 (1.40–1.51)     | 328.7            | <0.001           | 1.46 (1.40–1.52) | 328.7                 | <0.001           | 1.48 (1.41–1.54) | 337.6           | <0.001            | 1.48 (1.41–1.54) | 337.6            | <0.001            |
| BMI at time of transplantation         | 0.95 (0.94–0.96)     | 159.5            | <0.001           | 0.96 (0.96–0.97) | 159.5                 | <0.001           | 0.97 (0.96–0.98) | 162.8           | <0.001            | 0.97 (0.96–0.98) | 162.8            | <0.001            |
| Indigenous status x time (interaction) | –                    | –                | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| 3                                      | 0.02 (–0.23–0.26)    | 1.7              | 0.0894           | 0.01 (–0.24–0.26) | 0.8                  | 0.950            | –0.003 (–0.27–0.26) | –3              | 0.98            |
| 6                                      | 0.28 (0.03–0.53)     | 32.5             | 0.029            | 0.27 (0.02–0.53) | 31.4                  | 0.034            | 0.34 (0.07–0.61) | 40.9            | 0.012            |
| 12                                     | 0.60 (0.34–0.86)     | 81.8             | <0.001           | 0.59 (0.33–0.85) | 80.5                  | <0.001           | 0.61 (0.34–0.88) | 84.1            | <0.001            |
| 24                                     | 0.44 (0.16–0.72)     | 55.0             | <0.01            | 0.43 (0.15–0.71) | 54.0                  | <0.01            | 0.45 (0.16–0.74) | 57.1            | <0.01            |
| Recipient age, years                   | –                    | –                | –                | –0.03 (–0.033–0.026) | –2.9               | <0.001           | –0.03 (–0.04–0.03) | –3.1            | <0.001            |
| Gender                                  | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| Male                                    | –                    | –                | –                | –                | –                    | –                | –                | –                | –                    | –                | –                |
| Female                                  | 0.20 (0.11–0.28)     | 21.9             | <0.001           | 0.21 (0.12–0.31) | 23.6                  | <0.001           | –                | –                | –                    | –                | –                |
| Current smoking status                  | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| No                                      | –                    | –                | –                | –                | –                    | –                | –                | –                | –                    | –                | –                |
| Yes                                     | 0.09 (–0.03–0.21)    | 9.5              | 0.151            | 0.08 (–0.05–0.21) | 8.3                  | 0.245            | –                | –                | –                    | –                | –                |
| Diabetes Mellitus                       | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| No                                      | –                    | –                | –                | –                | –                    | –                | –                | –                | –                    | –                | –                |
| Yes                                     | 0.02 (–0.10–0.14)    | 2.0              | 0.748            | 0.01 (–0.12–0.15) | 1.4                  | 0.845            | –                | –                | –                    | –                | –                |
| Coronary artery disease                 | Reference            | – –              | –                | Reference        | – –                  | – –              | –                | Reference        | – –                  | – –              | –                |
| No                                      | –                    | –                | –                | –                | –                    | –                | –                | –                | –                    | –                | –                |
| Yes                                     | 0.17 (0.05–0.29)     | 18.6             | <0.01           | 0.18 (0.05–0.32) | 20.1                  | <0.01            | –                | –                | –                    | –                | –                |
| Variables                          | Univariate Model [1] | Multivariate Model 1[2] | Multivariate Model 2[3] |
|-----------------------------------|----------------------|-------------------------|-------------------------|
|                                   | Coefficient [4]      | RE % [5] | P value | Coefficient [4] (95% CI) | RE % [5] | P value | Coefficient [4] (95% CI) | RE % [5] | P value |
| Cerebrovascular disease           |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| No                                | –0.16 (–0.35–0.03)   | –14.7     | 0.095   | –0.18 (–0.39–0.03)      | –16.2   | 0.096   |
| Yes                               |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Peripheral vascular disease       |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| No                                | –0.04 (–0.20–0.11)   | –4.2      | 0.585   | –0.05 (–0.22–0.13)      | –4.5    | 0.600   |
| Yes                               | –0.02 (–0.03–0.01)   | –1.8      | < 0.001 | –0.02 (–0.03–0.02)      | –1.7    | < 0.001 |
| Total ischemia time               | –0.02 (–0.04–0.01)   | –1.6      | 0.222   | –0.01 (–0.04–0.02)      | –1.1    | 0.422   |
| HLA antigen mismatch              | –0.02 (–0.04–0.01)   | –1.6      | 0.222   | –0.01 (–0.04–0.02)      | –1.1    | 0.422   |
| Dialysis vintage                  |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Pre-emptive                       | –0.01 (–0.82–0.79)   | –1.2      | 0.977   | 0.01 (–0.87–0.89)       | 1.2     | 0.978   |
| < 1 year                          | –0.04 (–0.84–0.75)   | –4.4      | 0.912   | –0.01 (–0.89–0.86)      | –1.1    | 0.980   |
| 1–5 years                         | –0.14 (–0.94–0.66)   | –12.8     | 0.737   | –0.09 (–0.97–0.79)      | –8.3    | 0.846   |
| > 5 years                         |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Transplantation era               |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| 1995–1999                         | –0.05 (–0.18–0.07)   | –5.2      | 0.415   | –0.08 (–0.22–0.05)      | –8.0    | 0.235   |
| 2000–2004                         | 0.07 (–0.06–0.20)    | 7.4       | 0.283   | 0.04 (–0.10–0.18)       | 4.2     | 0.570   |
| 2005–2009                         | 0.14 (0.01–0.27)     | 15.2      | 0.029   | 0.12 (–0.03–0.26)       | 12.3    | 0.121   |
| 2010–2014                         | –0.01 (–0.01–0.004)  | –0.7      | < 0.001 | –0.01 (–0.01–0.004)     | –0.7    | < 0.001 |
| Donor age                         |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Male                              | 0.02 (–0.06–0.10)    | 1.9       | 0.663   | 0.02 (–0.07–0.11)       | 2.1     | 0.651   |
| Female                            |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Rejection                         |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| No                                | –0.10 (–0.20–0.004)  | –9.6      | 0.058   |
| Yes                               |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| Delayed graft function            |                      |           |         | Reference               | –       | –       | Reference               | –       | –       |
| No                                | –0.17 (–0.28–0.05)   | –15.3     | < 0.001 |
Table 2 Marginal mean change in BMI (Multivariate mixed effect model) between Indigenous and Non-Indigenous groups with confounders (Continued)

| Variables                      | Univariate Model 1 | Multivariate Model 1 | Multivariate Model 2 |
|--------------------------------|--------------------|----------------------|----------------------|
|                                 | Coefficient [4] (95% CI) | RE % [5] | P value | Coefficient [4] (95% CI) | RE % [5] | P value | Coefficient [4] (95% CI) | RE % [5] | P value |
| Prednisolone doses quarterly (mg) |                    |                      |                      |
| 0                               | −0.26 (−0.44–−0.09) | −22.9               | < 0.001             |
| 1–4.99 mg                       | 0.20 (−0.03–0.43)   | 29.7                | 0.08                |
| 5–6.99 mg                       | Reference           | –                    | –                   |
| 7–9.99 mg                       | −0.03 (−0.16–0.09)  | −3.0                | 0.59                |
| 10+ mg                          | −0.11 (−0.22–0.01)  | −10.4               | 0.06                |
| Constant/intercept              | 1.22 (0.98–1.46)    | < 0.001             | –                   |
|                                 | 2.87 (2.02–3.73)    | –                    | < 0.001             |
|                                 | 2.74 (1.80–3.69)    | –                    | < 0.001             |

1. Univariate model includes indigenous status, time post transplants and interaction between indigenous status and time post transplants
2. Multivariate model 1 includes variables from model 1 plus recipient's age, gender, smoking status, diabetes mellitus, comorbidities, ischemia time, HLA mismatches, dialysis vintage, transplant ERA, Donor's age and gender
3. Multivariate model 2 includes variables from multivariate model 1 plus rejection, delayed graft function, and prednisolone doses
4. Marginal mean change in BMI (kg/m²)
5. RE% corresponding to a coefficient expressed as expected percentage change in BMI calculated as \((\text{exp(coefficient)}-1)\) * 100
6. In addition to main effects (indigenous status and time), the interaction term (indigenous status x time) explains the BMI change between Indigenous and non-indigenous groups by different times post transplants
outcomes compared to non-indigenous Australians are predominantly due to infectious causes with rates of other causes such as cardiovascular disease and cancers appearing to be similar [13, 22]. These studies are limited by design issues (mostly retrospective analyses) and small sample sizes.

In some populations, high BMI and weight gain post-kidney transplantation is associated with post-transplant hypertension, diabetes mellitus, ischemic heart disease and poor graft and patient outcomes [9]. However, other studies have shown no association with patient or graft outcomes [23]. Some of these studies suggested that only demographic factors rather than treatment factors may contribute to the risk of weight gain post-kidney transplantation [5]. Young age, black ethnicity and female gender were associated with more weight gain in these studies [5]. Results from other studies conflicted these findings [24]. Our results agree with other studies suggesting an association of these factors with weight gain [5].

The higher BMI in Aboriginal and Torres Strait Islander Australians at transplantation and the higher weight gain throughout the first 2 years post-transplantation in all BMI categories (except for low BMI) can be explained by several possible factors as outlined above. The higher baseline BMI may reflect of higher rates of obesity in Aboriginal and Torres Strait Islander Australians [25] (consistent with previous data [15]) which partly explains the increased risk of CKD observed in this population. There is evidence to support an increased prevalence of the metabolic syndrome among Aboriginal and Torres Strait Islander Australians which positively correlates with prevalence rates of CKD [26]. From the results of a recent study, another potential explanation for the high BMI at the time of kidney transplantation and hence the post-transplantation weight gain is the difference in body composition and fat-free mass in Aboriginal and Torres Strait Islander Australians versus non-Indigenous Australians [27].

Some studies have shown no relationship between steroid dose and weight gain [8]. Our analysis included the potential effect of steroid use and other treatment factors (Table 2, model 2). Consistent with studies examining outcomes in Aboriginal and Torres Strait Islander Australians, the association of higher rejection rates with Aboriginal and Torres Strait Islander ethnicity may be associated with intermittent bursts of higher steroid dose exposure as treatment for rejection. This requires further exploration as a potential contributor to weight gain [13, 15, 22]. The lack of association with rejection (before stratifying BMI trajectories between Indigenous and non-Indigenous group by rejection) was surprising and needs further exploration. However, this

| Table 3 Immunosuppression regimens received during the course of the study and related BMI changes |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Immunosuppression regimens | Number (Percent) | Mean BMI (kg/m²) @Tx 3 M 6 M 12 M 24 M |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Azathioprine | 734 (11%) | 26.3 | 26.6 | 27.1 | 27.5 | 27.6 |
| Cyclosporin A | 3027 (46%) | 26.3 | 26.6 | 27.1 | 27.5 | 27.6 |
| Everolimus | 84 (1%) | 26.2 | 26.4 | 26.9 | 27.3 | 27.4 |
| Mycophenolate Mofetil | 4563 (70%) | 26.3 | 26.5 | 27.0 | 27.4 | 27.6 |
| Mycophenolate Sodium | 1041 (16%) | 26.7 | 27.0 | 27.5 | 27.8 | 28.0 |
| Prednisolone | 6527 (100%) | 26.3 | 26.6 | 27.1 | 27.5 | 27.6 |
| Sirolimus | 246 (4%) | 26.1 | 26.1 | 26.6 | 27.0 | 27.1 |
| Tacrolimus | 3530 (54%) | 26.6 | 26.8 | 27.3 | 27.8 | 28.0 |

Key: @Tx; at the time of transplantation, 3 M; at 3 months post-transplantation, 6 M; at 6 months post-transplantation, 12 M; at 12 month post-transplantation, 24 M; at 24 months post-transplantation

![Fig. 4 BMI changes by immunosuppression regimens over the study period](image)
is consistent with another previous study which reported no association [5]. This has further contributed to the uncertainty of this association [1].

The reason for the decrease in weight in the underweight BMI group is unclear. Although there were small numbers in the group (9 recipients), this may reflect either graft failure and return to dialysis or poorer health in that subgroup.

Clues as to why the weight trajectories differ between the two groups despite adjustment for all known confounders may also lie in variables that are not captured in data collected in the registry. Differences in diet, drug pharmacokinetics in different ethnic groups, healthy literacy level and other social factors are all important considerations.

Some studies of Aboriginal and Torres Strait Islander Australians have concluded that BMI may underestimate the cardiometabolic risks associated with overweight and obesity in this population [26–28]. These studies have indicated that due to differences in body fat distribution in Aboriginal and Torres Strait Islander Australians than Non-Indigenous populations, using anthropometric measurements (particularly waist circumference and waist/hip ratio measurements which may improve the cardio metabolic risk assessments than BMI) is a more accurate measure of overweight and obesity [26–28]. Including these anthropometric measurements for potential Aboriginal and Torres Strait Islander transplant recipients may give a further clarity on their value in predicting the weight changes after transplantation.

The weight change trajectories raise questions as to why this difference exists between Aboriginal and Torres Strait Islander and Non-Indigenous kidney transplant recipients. One study from North America reported African-American ethnicity as one of the factors associated with weight gain [29]. Hence, ethnicity may partly explain this difference between Aboriginal and Torres Strait Islander and Non-Indigenous Australians.

A recent clinical trial on reducing weight gain post transplantation by intensive nutritional intervention versus standard nutritional intake reported no benefit in the first year post transplantation [30]. There are other ongoing studies assessing other interventions such as lifestyle changes and lifestyle and dietary changes [31]. Given this lack of evidence, from our results, standard advice on reducing weight would apply to both Aboriginal and Torres Strait Islander and non-indigenous Australians although there is need for stronger emphasis in Aboriginal and Torres Strait Islander Australians.

Our results also raise further questions about weight change trajectory’s impact on graft and patient survival in Aboriginal and Torres Strait Islander Australians, which is beyond the scope of this paper but is highlighted as an area for future research.

We acknowledge limitations of our study are those inherent with the use of observational data. This includes the limitations inherent in the data collected for registries, for example ANZDATA does not collect information on lifestyle factors. The impact on post-transplant weight gain of pre-existing risk factors will be better assessed in a case-control study. Another limitation was the amount of missing data. The missing data is not entirely at random as at 24 months it was 9.7% due to graft loss or death or lost to follow-up and the missing at random was 16.9% (Fig. 5).

### Table 4 Marginal mean change in BMI (mixed effect model) rejection and non-rejection group

| Time post-transplant (months) | Indigenous status | No rejection (n = 4901) | Rejection (n = 1649) |
|------------------------------|-------------------|------------------------|---------------------|
|                              |                   | Coefficient (95% CI)   | RE %                | P value | Coefficient (95% CI) | RE % | P value |
| Indigenous status            |                   |                        |                     |         |                      |      |         |
| Non-Indigenous               | Reference         | –                      | –                   | –       | Reference            | –    | –       |
| Indigenous                   | 0.07 (−0.22–0.36) | 7.3                    | 0.651               | 0.04 (−0.37–0.47) | 4.1    | 0.839               |
| Time post-transplant (months)| Reference         | –                      | –                   | –       | Reference            | –    | –       |
| 0                            | 0.32 (0.26–0.38)  | 37.7                   | < 0.001             | 0.22 (0.10–0.33) | 24.6  | < 0.001             |
| 3                            | 0.84 (0.78–0.91)  | 131.6                  | < 0.001             | 0.69 (0.57–0.81) | 99.4  | < 0.001             |
| 6                            | 1.26 (1.20–1.33)  | 252.5                  | < 0.001             | 1.15 (1.03–1.27) | 215.8 | < 0.001             |
| 12                           | 1.47 (1.40–1.53)  | 334.9                  | < 0.001             | 1.43 (1.30–1.55) | 317.9 | < 0.001             |
| 24                           |                    |                        |                     |         |                      |      |         |

RE% corresponding to a coefficient expressed as expected percentage change in BMI, calculated as \((\exp(\text{coefficient})-1)\times100\)
However, the patient characteristics and confounders were analyzed by stratification of non-missing and missing data and this was found to be insignificant for almost all the characteristics in the Aboriginal and Torres Strait Islander group. Additionally, it could be argued that questions on the accuracy of BMI as a measure of overweight and obesity in Aboriginal and Torres Strait Islander Australians may affect the accuracy of this comparison as anthropometric measurements are more reliable than BMI in classifying Aboriginal and Torres Strait Islander patients into a particular weight category [28]. However, as this study compares weight change rather than absolute differences, this may not have a significant effect on the difference in weight change observed between the groups.

Conclusions
Aboriginal and Torres Strait Islander Australians have a higher weight-gain in the first 24 months following kidney transplantation than non-indigenous Australians in all categories of BMI except underweight. Post-transplantation weight-gain did not appear to be explained by transplant rejection. Post-transplantation health and cardio-metabolic risk is vital in promoting this form of renal replacement therapy, especially in populations known to have cardiovascular disease and poor kidney transplant outcomes. We recommend further studies examining: 1) the potential effects of treatment factors such as steroid use and the rates of rejection 2) the potential relationship of this weight gain with transplant and patient outcomes.

Implications for clinical practice
Equitable access to kidney transplantation is a public health issue [32]. Aboriginal and Torres Strait Islander Australians, who suffer some of the highest rates of CKD in the world, would benefit from kidney transplantation [33]. However, access to kidney transplantation is currently low [14, 34–36]. One of the factors
associated with the poor access is poor graft and patient outcomes which are common among Aboriginal and Torres Strait Islander Australians [13, 22]. Improving the understanding and management of risk factors for poor outcomes will improve access. Our study demonstrates significant weight gain post transplantation. Determining the effect of this weight gain on graft and patient survival may lead to improvement in outcomes and hence access to kidney transplantation.

Abbreviations

ANZDATA: Australia and New Zealand Dialysis and Transplant Registry; BMI: Body mass index; CKD: Chronic kidney disease; HD: Haemodialysis; HLA: Human leucocyte antigens; PD: Peritoneal dialysis

Acknowledgments

We acknowledge the Australia and New Zealand Dialysis and Transplant Registry and for their support in providing data for this study. We also acknowledge all the renal units and patients across Australia who contribute data to the registry.

Authors’ contributions

SWM, SU, JC, JH, and SM all made substantial contribution to the conceptualization and design, acquisition of data, analysis and interpretation of data. SWM and JC drafted the article, and all authors listed played an important role in revising the manuscript for intellectual content. All authors provided final approval of the version to be published and are accountable for all aspects of the work.

Funding

The study did not need and was not funded.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) http://www.anzdata.org.au/v1/. Data is available according to ANZDATA data release guidelines.

Ethics approval and consent to participate

Our study is on registry data and, approval was obtained from the custodians of ANZDATA. ANZDATA is based at the South Australian Health and Medical Research Institute (SAHMRI) and the activities of the registry have been granted full ethics approval by the Royal Adelaide Hospital Human Research Ethics Committee (reference number: HREC/17/RAH/408 R2017/02/27, approval date: 28/11/2017). ANZDATA receives demographic and clinical information through voluntary submissions from all renal units in Australia and New Zealand. Data collection and use is authorized through an informed consent form. All authors provided final approval of the version to be published and are accountable for all aspects of the work.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Nephrology, Division of Medicine, Royal Darwin Hospital, P.O. Box 41326, Casuarina, Darwin, Northern Territory, Australia. 2Flinders University and Northern Territory Clinical School, Royal Darwin Hospital Campus, Darwin, Australia. 3Menzies School of Health Research Charles Darwin University, Darwin, NT, Australia. 4Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, SA Health and Medical Research Institute, Adelaide, Australia. 5Central Northern Adelaide Renal and Transplantation Services, Royal Adelaide Hospital, Adelaide, Australia. 6Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.

Received: 18 November 2018 Accepted: 6 June 2019
Published online: 25 June 2019

References

1. Clunk JM, Lin CY, Curtis JJ. Variables affecting weight gain in renal transplant recipients. Am J Kidney Dis. 2003;38:349–53.
2. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.
3. Grosso G, Corona D, Mistretta A, et al. The role of obesity in kidney transplantation outcome. Transplant Proc. 2012;44:1864–8.
4. Chadban S, Chan M, Fy k Y, et al. The CARI guidelines. Nutritional management of overweight and obesity in adult kidney transplant recipients. Nephrology (Carlton). 2010;15(Suppl 1):552–5.
5. Johnson CP, Gallagher-Lepak S, Zhu YR, et al. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–7.
6. Moore LW, Gaber AO. Patterns of early weight change after renal transplantation. J Ren Nutr. 1996;6:21–5.
7. Teplan V, Poledine R, Schuck O, Ritz E, Vitko S. Hyperlipidaemia and obesity after renal transplantation. Ann Transplant. 2001;6:21–3.
8. Diaz JM, Sainz Z, Oliver A, et al. Post-renal transplantation weight gain: its causes and its consequences. Transplant Proc. 2005;37:3839–41.
9. el-Agroudy AE, Wafa EW, Ghelieh OE, Shehab el-Dein AB, Ghoneim MA. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation. 2004;77:1381–5.
10. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6:357–63.
11. Mucha K, Foroncewicz B, Ryter M, et al. Weight gain in renal transplant recipients in a polish single centre. Ann Transplant. 2015;20:16–20.
12. Chang SH, McDonald SP. Post-kidney transplant weight change as marker of poor survival outcomes. Transplantation. 2008;85:1443–8.
13. Rogers NM, Lawton PD, Jose MD. Kidney transplant outcomes in the indigenous population in the Northern Territory of Australia. Transplantation. 2006;82:882–6.
14. Cass A, Devitt J, Preece C, et al. Barriers to access by indigenous Australians to kidney transplantation: the IMPAKT study. Nephrology (Carlton). 2004;9(Suppl 1):144–6.
15. McDonald S. Indigenous transplant outcomes in Australia: what the ANZDATA registry tells us. Nephrology (Carlton). 2004;9(Suppl 1):538–43.
16. Aboriginal and Torres Strait islander health performance framework 2014 Report Australian Government, 2014. at https://www.pmc.gov.au/sites/default/files/publications/indigenous/Health-Performance-Framework-2014/ tier-2-determinants-health/222-overweight-and-obesity.html. Accessed 24 Aug 2018.
17. Cardiovascular disease, diabetes and chronic kidney disease - Australian facts: aboriginal and Torres Strait islander people. Canberra: Australian Institute of Health and Welfare, 2015. at https://www.aihw.gov.au/reports/heart-stroke-vascular-disease/cardiovascular-disease-chronic-kidney-indigenous/contents/table-of-contents. Accessed 24 Aug 2018.
18. National Health and Medical Research Council (Australia). Nutrition in Aboriginal and Torres Strait Islander peoples : an information paper / National Health and Medical Research Centre, vol. 2000. Canberra: National Health and Medical Research Council, 2000.
19. The relationship between overweight, obesity and cardiovascular disease: a literature review prepared for the National Heart Foundation Australia: Australian Institute of Health and Welfare (AIHW); 2004. https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/relationship-overweight-obesity-cardiovascular-contents/table-of-contents. Accessed 23 Nov 2017.
20. World Health Organization. Obesity: preventing and managing the global epidemic report of a WHO consultation (WHO technical report series 894): World Health Organization (Geneva 27, Switzerland); 2000.
21. McDonald SP, Hoy WE. Interfaces between cardiovascular and kidney disease among aboriginal Australians. Adv Chronic Kidney Dis. 2005;12:39–48.
22. Rogers NM, Lawton PD, Jose MD. Plasma cell infiltrates and renal allograft outcomes in indigenous and non-indigenous people of the Northern Territory of Australia. Nephrology (Carlton). 2011;16:777–83.
23. Marcon R, Fernandez A, Pascual J, et al. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome. Transplant Proc. 2007;39:2205–7.
24. Cashion AK, Sanchez ZV, Cowan PA, Hathaway DK, Lo Costello A, Gaber AO. Changes in weight during the first year after kidney transplantation. Prog Transplant. 2007;17:40–7.
25. Lucero AA, Lambrick DM, Faulkner JA, et al. Modifiable cardiovascular disease risk factors among indigenous populations. Adv Prev Med. 2014;2014:547018.
26. Hughes JT, O’Dea K, Piers K, et al. Associations of serum adiponectin with markers of cardio-metabolic disease risk in indigenous Australian adults with good health, diabetes and chronic kidney disease. Obes Res Clin Pract. 2016:99–72.
27. Hughes JT, Maple-Brown LJ, Piers LS, Merkin J, O’Dea K, Ward LC. Development of a single-frequency bioimpedance prediction equation for fat-free mass in an adult indigenous Australian population. Eur J Clin Nutr. 2015:95–99.
28. Kondalsamy-Chennakesavan S, Hoy WE, Wang Z, et al. Anthropometric measurements of Australian aboriginal adults living in remote areas: comparison with nationally representative findings. Am J Hum Biol. 2008;20:317–24.
29. Baum CL, Thielke K, Westin E, Kogan E, Cicaless L, Benedetti E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition. 2002;18:139–46.
30. Henggeler CK, Plank LD, Ryan KJ, et al. A randomized controlled trial of an intensive nutrition intervention versus standard nutrition care to avoid excess weight gain after kidney transplantation: the INTENT trial. J Ren Nutr. 2018;28(5):340–51.
31. Klaassen G, Zelle DM, Navis G, et al. Lifestyle intervention to improve quality of life and prevent weight gain after renal transplantation: Design of the Active Care after transplantation (ACT) randomized controlled trial. BMC Nephrol. 2017;18:296.
32. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation. 2012;94:703–13.
33. Hoy WE, Mott SA, Mc Donald SP. An expanded nationwide view of chronic kidney disease in aboriginal Australians. Nephrology (Carlton). 2016;21:1916–22.
34. Majoni SW, Abeyaratne A. Renal transplantation in indigenous Australians of the Northern Territory: closing the gap. Intern Med J. 2013;43:1059–66.
35. Sypek MP, Clayton PA, Lim W, et al. Access to waitlisting for deceased donor kidney transplantation in Australia. Nephrology (Carlton). 2018. Aug 30. https://doi.org/10.1111/nep.13484. (Epub ahead of print).
36. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. Renal transplantation for indigenous Australians: identifying the barriers to equitable access. Ethn Health. 2003;8:111–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.